Hyperprolactinemia resident survival guide: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
Line 59: Line 59:


==Treatment==
==Treatment==
Shown below is an algorithm summarizing the treatment of [[hyperprolactinemia]]<ref name="pmid21296991">{{cite journal| author=Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA | display-authors=etal| title=Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 2 | pages= 273-88 | pmid=21296991 | doi=10.1210/jc.2010-1692 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21296991  }} </ref><ref name="pmid16886971">{{cite journal| author=Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD | display-authors=etal| title=Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. | journal=Clin Endocrinol (Oxf) | year= 2006 | volume= 65 | issue= 2 | pages= 265-73 | pmid=16886971 | doi=10.1111/j.1365-2265.2006.02562.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16886971  }} </ref><ref name="pmid7915824">{{cite journal| author=Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF| title=A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. | journal=N Engl J Med | year= 1994 | volume= 331 | issue= 14 | pages= 904-9 | pmid=7915824 | doi=10.1056/NEJM199410063311403 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7915824  }} </ref><ref name="pmid6681646">{{cite journal| author=Randall RV, Laws ER, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW| title=Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. | journal=Mayo Clin Proc | year= 1983 | volume= 58 | issue= 2 | pages= 108-21 | pmid=6681646 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6681646  }} </ref>: 
{{Family tree/start}}
{{Family tree/start}}
{{Family tree | | | | A01 | | | |A01= The prolactinoma are treated in the following patients<ref name="pmid16886971">{{cite journal| author=Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD | display-authors=etal| title=Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. | journal=Clin Endocrinol (Oxf) | year= 2006 | volume= 65 | issue= 2 | pages= 265-73 | pmid=16886971 | doi=10.1111/j.1365-2265.2006.02562.x | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16886971  }} </ref><ref name="pmid21296991">{{cite journal| author=Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA | display-authors=etal| title=Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 2 | pages= 273-88 | pmid=21296991 | doi=10.1210/jc.2010-1692 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21296991  }} </ref><ref name="pmid32130815">{{cite journal| author=Melmed S| title=Pituitary-Tumor Endocrinopathies. | journal=N Engl J Med | year= 2020 | volume= 382 | issue= 10 | pages= 937-950 | pmid=32130815 | doi=10.1056/NEJMra1810772 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32130815  }} </ref>:
{{Family tree | | | | A01 | | | |A01= The prolactinoma are treated in the following patients:
* A macroadenoma causing neurological symptoms such as headache and visual impairment due to compression of the optic chiasm.
* A macroadenoma causing neurological symptoms such as headache and visual impairment due to compression of the optic chiasm.
* Hypogonadism and galactorrhea due to increased prolactin secretion.
* Hypogonadism and galactorrhea due to increased prolactin secretion.
Line 66: Line 67:
}}
}}
{{Family tree | |,|-|-|^|-|-|.| | }}
{{Family tree | |,|-|-|^|-|-|.| | }}
{{Family tree | B01 | | | | B02 |B01= The drug of choice for prolactinoma are dopamine agonists as they decrease prolactin secretion and reduce the size of the prolactinoma.<ref name="pmid6229205">{{cite journal| author=Vance ML, Evans WS, Thorner MO| title=Drugs five years later. Bromocriptine. | journal=Ann Intern Med | year= 1984 | volume= 100 | issue= 1 | pages= 78-91 | pmid=6229205 | doi=10.7326/0003-4819-100-1-78 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6229205  }} </ref><ref name="pmid22828169">{{cite journal| author=Wang AT, Mullan RJ, Lane MA, Hazem A, Prasad C, Gathaiya NW | display-authors=etal| title=Treatment of hyperprolactinemia: a systematic review and meta-analysis. | journal=Syst Rev | year= 2012 | volume= 1 | issue=  | pages= 33 | pmid=22828169 | doi=10.1186/2046-4053-1-33 | pmc=3483691 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22828169  }} </ref> Cabergoline is the preferred drug because of its efficacy and lower incidence of nausea and side effects compared to bromocriptine.<ref name="pmid7915824">{{cite journal| author=Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF| title=A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. | journal=N Engl J Med | year= 1994 | volume= 331 | issue= 14 | pages= 904-9 | pmid=7915824 | doi=10.1056/NEJM199410063311403 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=7915824  }} </ref><ref name="pmid8964874">{{cite journal| author=Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, Simons JA | display-authors=etal| title=Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. | journal=J Clin Endocrinol Metab | year= 1996 | volume= 81 | issue= 6 | pages= 2338-43 | pmid=8964874 | doi=10.1210/jcem.81.6.8964874 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8964874  }} </ref> | B02= Transsphenoidal surgery is done in:
{{Family tree | B01 | | | | B02 |B01= The drug of choice for prolactinoma are dopamine agonists as they decrease prolactin secretion and reduce the size of the prolactinoma. Cabergoline is the preferred drug because of its efficacy and lower incidence of nausea and side effects compared to bromocriptine. | B02= Transsphenoidal surgery is done in:
* Patients with unsuccessful treatment with dopamine agonists.  
* Patients with unsuccessful treatment with dopamine agonists.  
* A female patient with a known history of lactotroph macroadenoma who wishes to conceive.
* A female patient with a known history of lactotroph macroadenoma who wishes to conceive. }}
* Transsphenoidal surgery has a high success rate in reducing serum prolactin to a normal level.<ref name="pmid8626821">{{cite journal| author=Feigenbaum SL, Downey DE, Wilson CB, Jaffe RB| title=Transsphenoidal pituitary resection for preoperative diagnosis of prolactin-secreting pituitary adenoma in women: long term follow-up. | journal=J Clin Endocrinol Metab | year= 1996 | volume= 81 | issue= 5 | pages= 1711-9 | pmid=8626821 | doi=10.1210/jcem.81.5.8626821 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=8626821  }} </ref> <ref name="pmid6681646">{{cite journal| author=Randall RV, Laws ER, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW| title=Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients. | journal=Mayo Clin Proc | year= 1983 | volume= 58 | issue= 2 | pages= 108-21 | pmid=6681646 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=6681646  }} </ref> }}
{{familytree | |!| | | | | |!| | | }}
{{familytree | |!| | | | | | | | | | | | | | }}
{{Family tree | C01 | | | |C02| C01= The preferred initial dose of cabergoline for microadenoma is 0.25mg twice a week or 0.5mg once a week. The medicine should be given at dinner or bedtime to reduce the incidence of nausea and drowsiness. | C02= Transsphenoidal surgery has a high success rate in reducing serum prolactin to a normal level. }}
{{Family tree | C01 | | | | |C01= The preferred initial dose of cabergoline for microadenoma is 0.25mg twice a week or 0.5mg once a week. The medicine should be given at dinner or bedtime to reduce the incidence of nausea and drowsiness.<ref name="pmid21296991">{{cite journal| author=Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA | display-authors=etal| title=Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. | journal=J Clin Endocrinol Metab | year= 2011 | volume= 96 | issue= 2 | pages= 273-88 | pmid=21296991 | doi=10.1210/jc.2010-1692 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21296991  }} </ref> }}
{{familytree | |!| | | | | | | | | | | | | | }}
{{Family tree | D01 | | | | |D01= Cabergoline is also preferred by women who wish to conceive as it is safe in early pregnancy.<ref name="pmid12401507">{{cite journal| author=Ricci E, Parazzini F, Motta T, Ferrari CI, Colao A, Clavenna A | display-authors=etal| title=Pregnancy outcome after cabergoline treatment in early weeks of gestation. | journal=Reprod Toxicol | year= 2002 | volume= 16 | issue= 6 | pages= 791-3 | pmid=12401507 | doi=10.1016/s0890-6238(02)00055-2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=12401507  }} </ref> Though bromocriptine is also a safe choice with more evidence of reduced events of congenital defects.<ref name="pmid25996397">{{cite journal| author=| title=Reorganized text. | journal=JAMA Otolaryngol Head Neck Surg | year= 2015 | volume= 141 | issue= 5 | pages= 428 | pmid=25996397 | doi=10.1001/jamaoto.2015.0540 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25996397  }} </ref> }}
{{Family tree/end}}
{{Family tree/end}}


Revision as of 16:36, 11 August 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Hyperprolactinemia is defined as high circulating levels of prolactin in the blood. The cut-off values of serum prolactin for hyperprolactinemia are greater than 20 ng/ml in men and postmenopausal women and greater than 30ng/ml in premenopausal women.[1] Prolactin hormone is produced by lactotroph cells located in the anterior lobe of the pituitary gland. It is responsible for lactation and the development of breasts in females during pregnancy. Elevated levels of prolactin cause galactorrhea, menstrual irregularities, and failure to conceive in females and erectile dysfunction, hypogonadism, and infertility in males. This section provides a short and straight to the point overview of the hyperprolactinemia.

Causes

Life Threatening Causes

Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.

  • Severe burns on the chest can cause hyperprolactinemia due to neural stimulation similar to suckling. [2]

Common Causes

Diagnosis

Shown below is an algorithm summarizing the diagnosis of hyperprolactinemia according to an Endocrine Society Clinical Practice guidelines[1][11]:

 
 
 
Characterize the symptoms
  • headache
  • oligomenorrhea
  • infertility
  • hypogonadism
  • erectile dysfunction
  • galactorrhea
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Inquire about any present illness like hypothyroidism, chronic renal failure, and the use of medications known to cause hyperprolactinemia.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Measure serum prolactin. Elevated serum prolactin
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mesure serum TSH. TSH levels elevated?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yes
 
 
No
 
 
 
 
 
 
 
 
 
 
 
Treat hypothyroidism
 
 
Perform the MRI with the contrast of the brain. Does it show any mass in the hypothalamic-pituitary region?
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Levels of TSH and prolactin should be reassessed after 6-12 weeks.
 
Yes. The levels of other pituitary hormones should be evaluated: Plasma corticotropins (ACTH), Serum TSH, Insulin-like growth factors, Follicle-stimulating hormone, Luteinizing hormone, Estradiol/ Testosterone
 
No

Treatment

Shown below is an algorithm summarizing the treatment of hyperprolactinemia[1][12][13][14]:

 
 
 
The prolactinoma are treated in the following patients:
  • A macroadenoma causing neurological symptoms such as headache and visual impairment due to compression of the optic chiasm.
  • Hypogonadism and galactorrhea due to increased prolactin secretion.
  • Infertility in women with disrupted luteal phase.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The drug of choice for prolactinoma are dopamine agonists as they decrease prolactin secretion and reduce the size of the prolactinoma. Cabergoline is the preferred drug because of its efficacy and lower incidence of nausea and side effects compared to bromocriptine.
 
 
 
Transsphenoidal surgery is done in:
  • Patients with unsuccessful treatment with dopamine agonists.
  • A female patient with a known history of lactotroph macroadenoma who wishes to conceive.
 
 
 
 
 
 
 
 
 
 
 
 
 
The preferred initial dose of cabergoline for microadenoma is 0.25mg twice a week or 0.5mg once a week. The medicine should be given at dinner or bedtime to reduce the incidence of nausea and drowsiness.
 
 
 
Transsphenoidal surgery has a high success rate in reducing serum prolactin to a normal level.

Do's

  • The content in this section is in bullet points.

Don'ts

  • Certain medications like risperidone, domperidone, methyldopa, metoclopramide, verapamil, and cimetidine raise serum prolactin levels. These medications can blunt the effects of dopamine agonists.
  • The patients should be monitored for side effects. Cabergoline treatment in prolactinoma patients for more than three months can result in impulse control disorders. Hypersexuality is common in males and compulsive eating disorders in females.[15]

References

  1. ↑ 1.0 1.1 1.2 Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA; et al. (2011). "Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 96 (2): 273–88. doi:10.1210/jc.2010-1692. PMID 21296991.
  2. ↑ Morley JE, Dawson M, Hodgkinson H, Kalk WJ (1977). "Galactorrhea and hyperprolactinemia associated with chest wall injury". J Clin Endocrinol Metab. 45 (5): 931–5. doi:10.1210/jcem-45-5-931. PMID 562902.
  3. ↑ 3.0 3.1 Tyson JE, Hwang P, Guyda H, Friesen HG (1972). "Studies of prolactin secretion in human pregnancy". Am J Obstet Gynecol. 113 (1): 14–20. doi:10.1016/0002-9378(72)90446-2. PMID 5024994.
  4. ↑ 4.0 4.1 Kleinberg DL, Noel GL, Frantz AG (1977). "Galactorrhea: a study of 235 cases, including 48 with pituitary tumors". N Engl J Med. 296 (11): 589–600. doi:10.1056/NEJM197703172961103. PMID 840242.
  5. ↑ David SR, Taylor CC, Kinon BJ, Breier A (2000). "The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia". Clin Ther. 22 (9): 1085–96. doi:10.1016/S0149-2918(00)80086-7. PMID 11048906.
  6. ↑ McCallum RW, Sowers JR, Hershman JM, Sturdevant RA (1976). "Metoclopramide stimulates prolactin secretion in man". J Clin Endocrinol Metab. 42 (6): 1148–52. doi:10.1210/jcem-42-6-1148. PMID 777023.
  7. ↑ Sowers JR, Sharp B, McCallum RW (1982). "Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man". J Clin Endocrinol Metab. 54 (4): 869–71. doi:10.1210/jcem-54-4-869. PMID 7037817.
  8. ↑ Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A (1976). "Effects of methyldopa on prolactin and growth hormone". Br Med J. 1 (6019): 1186–8. doi:10.1136/bmj.1.6019.1186. PMC 1639736. PMID 1268617.
  9. ↑ Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M; et al. (2013). "Mutant prolactin receptor and familial hyperprolactinemia". N Engl J Med. 369 (21): 2012–2020. doi:10.1056/NEJMoa1307557. PMC 4209110. PMID 24195502.
  10. ↑ Snyder PJ, Jacobs LS, Utiger RD, Daughaday WH (1973). "Thyroid hormone inhibition of the prolactin response to thyrotropin-releasing hormone". J Clin Invest. 52 (9): 2324–9. doi:10.1172/JCI107421. PMC 333037. PMID 4199418.
  11. ↑ Majumdar A, Mangal NS (2013). "Hyperprolactinemia". J Hum Reprod Sci. 6 (3): 168–75. doi:10.4103/0974-1208.121400. PMC 3853872. PMID 24347930.
  12. ↑ Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bronstein MD; et al. (2006). "Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas". Clin Endocrinol (Oxf). 65 (2): 265–73. doi:10.1111/j.1365-2265.2006.02562.x. PMID 16886971.
  13. ↑ Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, Scanlon MF (1994). "A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group". N Engl J Med. 331 (14): 904–9. doi:10.1056/NEJM199410063311403. PMID 7915824.
  14. ↑ Randall RV, Laws ER, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW (1983). "Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas. Results in 100 patients". Mayo Clin Proc. 58 (2): 108–21. PMID 6681646.
  15. ↑ Dogansen SC, Cikrikcili U, Oruk G, Kutbay NO, Tanrikulu S, Hekimsoy Z; et al. (2019). "Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study". J Clin Endocrinol Metab. 104 (7): 2527–2534. doi:10.1210/jc.2018-02202. PMID 30848825.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=Hyperprolactinemia_resident_survival_guide&oldid=1649958"